

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – January 11, 2012 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call To Order**
 - A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. December 14, 2011 DUR Minutes – Vote
 - B. December 15, 2011 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

4. **Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review for September 2011
 - B. Retrospective Drug Utilization Review Response for August 2011
 - C. Medication Coverage Activity Audit for December 2011
 - D. Pharmacy Help Desk Activity Audit for December 2011
 - E. Pharmacy Lock-In Program Report for Calendar Year 2011

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

5. **Action Item – Vote to Prior Authorize Brilinta™ – See Appendix C.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

6. **Action Item – Vote to Prior Authorize Xarelto® – See Appendix D.**
 - A. Product Summary
 - B. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

7. **30 Day Notice to Prior Authorize Select Prenatal Vitamin Products – See Appendix E.**
 - A. Utilization Review
 - B. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. **30 Day Notice to Prior Authorize Soliris[®] – See Appendix F.**
 - A. Introduction
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

9. **30 Day Notice to Prior Authorize Onfi[™] – See Appendix G.**
 - A. Product Summary
 - B. COP Recommendations
 - C. Product Details

Items to be presented by Dr. Moore, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of Ribavirin Miscellaneous Products – See Appendix H.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

11. **Action Item – Annual Review of Nasal Allergy Products – See Appendix I.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorization Review
 - D. Market News and Updates
 - E. COP Recommendations
 - F. Utilization Details

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

12. **FDA and DEA Updates – See Appendix J.**
13. **Future Business**
 - A. Annual Review of Narcotics
 - B. Annual Review of Erythropoiesis Stimulating Agents
 - C. New Product Reviews
 - D. Medical Product Reviews
14. **Adjournment**